Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroquinone is a small molecule topical depigmenting agent used to lighten areas of hyperpigmented skin such as freckles, age spots (lentigines), melasma (chloasma), and other forms of unwanted melanin hyperpigmentation. It works by temporarily inhibiting the enzymatic conversion of tyrosine to melanin by melanocytes in the skin, thereby reducing pigment production and leading to gradual lightening of darkened areas. Hydroquinone is available in various topical formulations (creams, emulsions) at concentrations typically ranging from 2% to 8%. It is considered the standard treatment for many forms of acquired hyperpigmentation but may cause local side effects such as redness or irritation[1][2][3][4][5][8]. Combination products with corticosteroids and retinoids are sometimes used for enhanced efficacy. The FDA no longer approves OTC hydroquinone creams.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroquinone.